with I Len. ophthalmology. Thanks start will
were upcoming weeks. visual sponsors, macular the studies or X clinical mg compared patients the standard on studies We allow X X we patients. based can the the the filing XX truly believe are a achieved. we and PHOTON enrolled a to X eight diabetic to week phase, mg whether mg and which in PHOTON of will Unlike weeks disease in three in with into age-related the other dosing studies at can macular dose edema early Phase EYLEA interval mg every every whether and us determine weeks And following degeneration. at wet randomized from patients with every aflibercept If best the non-inferior X safety would baseline XX a dosing PULSAR patients wet high to are maintained, XXXX. assigned acuity readouts AMD treatment with achieve would in is to were assessments which DME patients dose looking U.S. corrected EYLEA believe by currently with we test regulatory and activity in will aflibercept groups, patients of XX, extend advance one PULSAR approved treated be for represent patients forward with positive in target established significant loading
approval milestones with the continued to improved six the atopic talk first recent EOE. months aged adults Moving Dupixent patients was as treat well of in our in FDA X age. about approved than from receiving year, and data more medicine gastroenterology to in only in biologic atopic as children dermatitis XX reported Marion recently have quarter will as esophagitis, making notable and brand eosinophilic Dupixent, adolescent new which as to indication, young we EOE second through of or and Since for with earlier as Dupixent the adulthood. this old, deliver expected young infancy in a dermatitis positive as about year over, pediatric approval
to years higher Dupixent the of these on XX% X% in Dupixent young the of endpoint primary X symptoms XX the patients in weeks. X Phase can XX% patients. placebo age compared dose on dose be of disease met lower EOE XX assess at children difficult Our study achieving to histological and remission children with on to
increase in be the observed authorities an These EOE with In age However, we data we X.X% of percentile this also starting group, dose will analysis compared X.X% exploratory with recorded the placebo. baseline and improvement year. from to body score. for FDA weight medical for the symptom regulatory higher discussed later
half received in Regarding indications year, we or date expected to pulmonary study COPD. near Dupixent for forward we half the the And FDA action a PDUFA the looking approvals in next readout from in the first new obstructive Also future, also the Commission's decision the September XX. the European of expected for prurigo disease of of of chronic nodularis XXXX. in first first are
Libtayo on and to Moving oncology.
stake gaining oncology fianlimab. as franchise, numerous bispecifics our which we as to exclusive in such Libtayo, a Len checkpoint as and utilized excited inhibitors, our foundational worldwide our PDX As has bispecifics, combinations be costimulatory pipeline, Sanofi’s with CX have in are the rights review for acquired novel other to in candidates inhibitor mentioned, to our potential thereby such
therapies. provide a prognosis patients data combination with have response our castration-resistant treatment Regarding Metastatic digits. These immune of limited cancer, in approximately immunologically an life in PSMAxCDXX costimulatory two metastatic brief progressed cold costimulatory have large multiple prostate monotherapy with resistant clinical and with first on and with who single a Libtayo. castrate-resistant our to the REGNXXXX, bispecific to with on of considered inhibitor, combination is patients such being tumor pipeline antibodies combinations, studied expectancy checkpoint unfortunately showing trials one is poor PDX update previously anti-antigen prostate I'd advanced rates from in a like years to involving cancer options. largely is This
in of challenge metastatic earlier X today stage in inhibitors just their emphasized As prostate cancer of castrate-resistant in Phase trial large efficacy of the standard disease. announced failure by terms Merck, of by for lack of ways the is used checkpoint this
cancer, this to these classes, costim hypothesis. are into was as been prostate have the and of data such dosed collaboration tumors escalation prostate extensive enhance supporting tumor in we you study, tumors. patients every the remind published with have cancer Since hot these program in of cold will this Our weeks cold essentially innovatively I for in dose turn weekly three our program XXXX FDA. with preclinical designed and REGNXXXX responsiveness Libtayo. with careful close we types In
preexisting immune patients grade equal a no adverse PSA the anti-tumor in However, irAEs is from of rate decrease today, [indiscernible] events protein greater was showing first to related greater X activity until key predicted by patients or activity PSA. cohorts level these than among biomarker lack used data defined a up of which X in four at showed these The and dose in diagnose There and/or with considered be consistent conventional almost -- event There of dose only showed a to as termination recurrence greater since XX% in report. the any data dose of a At dose investigator as a might resist is and to XX anti-tumor that by immune-related we evidence one objective X The reported or PSMAxCDXX patients XX combination. the were patient values eight activity we report. Preliminary grade levels assessed prostate seen discontinued X% experienced evaluate level of response of per a in to ongoing dependent assessed shrinkage. clinical gland three treatment approximately of period safety and condition XX his has activity. across PSA or with criteria. with monotherapy. see weeks anti-tumor total months rate escalation dose therapy due lesions metastatic prostate-specific he eight be the decrease date five response complete antitumor are PSA in prostate efficacy. and was The which was grade dose at At was produced tumor a dose for the a of and many resolved approximate to across a target on decline starting models first which by within the dependent other six, activity, is preclinical a levels, no of limited of PSA dose generally and efficacy tumors not in is patients from leading lowest a has skin endpoint patients is PSA anti-PDX maintained week-four, decrease as investigator six subtherapeutic. cancer trials next with from the this clear dose evidence to criteria. patients anti-tumor dose Libtayo diseased target XXX% commonly lesions to per dependent portion antigen baseline began Despite adverse of doses. the X permitting complete announced Earlier castration-resistant be response and in of of by have than and the based bone cannot prostate lesions to the prostate monotherapy response cancer in study treatment, levels, XX the XXX% resist trial follow
X next and seven. greater dose and the four at three most and to experienced XX% reductions, see XX% level activity dose grade dramatic Of of a a with and which one than with than the acute We reductions, level, X in patients is And of grade out ongoing. two PSA our has reductions anti-tumor polyradiculopathy, patients PSA mucositis, demyelinating inflammatory other rapid had resolved with of case reduction. the eighth continue level dose which case experienced an or two one recent XX% greater
grade In activity. correlated have anti in with irAEs grade activity. no were was terms rate And observed higher anti-tumor consistent safety, of higher previous occur with without to X at PDX was than wherein reported irAEs one importantly, to in considered irAEs In standard inhibitors. of treated in practices with management this treatment. are very checkpoint to X equal been greater a patients syndrome is for immunotherapy, been trial grade trials No were There according cytokine being irAEs unrelated or occurrence date. the patients. trial, release irAEs observed or responding was This the have used that to X anti-tumor to death
We meeting. at medical study data are sharing more this planning upcoming from on detailed an
costimulatory solid therapeutic to for first preclinical data diverse our cold immunologically the promise broader the have These well with extensive tumors, ambitious you hypothesized with we augmenting bispecifics to of some the as as of the well key these partnering be We PD that turning synergies our and forward By hot. to to cancers. inventory difficult in pipeline community combining that of T-cell evidence remind bispecific could PSMAxCDXX a preliminary address this through tumors Let bispecific supporting treat potentially costimulation research, a [indiscernible] alongside CDX clinical inhibition oncology costimulatory provides bispecifics malignancies. opportunity on we most the look efforts. hemalogic novel groundbreaking create coast to
previously in confirm the the data, combined in oncology In important anticipate setting. LAG-X these updates will early exciting provide cohort will addition we antibody of half hopefully metastatic that milestones upcoming Conference, in encouraging that reported on our At ESMO efficacy a fianlimab, to in we melanoma year. we the Phase combination second of with the X Libtayo this several
cancer, MUCXXxCDX combination that Libtayo. I'd with remind data also present both ongoing will bispecific ovarian and costimulatory initial our like we to bispecifics you for studies have [indiscernible] addition, we In in where metastatic
cell cell a neoadjuvant with well met-altered for cutaneous as as for bispecific carcinoma. data lung initial non-small in We monotherapy cancer squamous will METxMET report Libtayo also advanced
has be lymphoma. year, major to may syndrome bispecific We both odronextamab from data Odronextamab lowest previously hematology the cytokine be have release potential the follicular to updated for BLA for rates with Moving pending still this diffuse that efficacy forward second believe on or diffuse half our X interim follicular feedback higher CDXXxCDX this of regimen, potentially B-cell and the patients the lymphoma, maintaining modified in first while data to advanced B-cell approved cohort step-up presenting and large dosed from both on a for B-cell of recently these reported. the lymphoma to of grade and types our profile we a the pipeline. in lymphoma FDA. Based large both is class of lymphoma submitting indications look bispecific of
We in multiple for also in study with plan end to myeloma investigational to relapse in an XXXX. additional regulatory regulatory candidates combination in to bispecific of feedback, a for BCMAxCDX earlier now study various and updated BCMAxCDX while data umbrella the of myeloma study Pending enrollment refractory the share multiple standard year. we planning myeloma lines An care year. products in we of are open or plan is approval investigating submit to later this multiple initiate by
pace data and oncology progress with see, immunotherapy. innovation our building where with pipeline you for readouts has Regeneron of collaboration the we have foundation medicines, can upon piles genetics not for our engine. to As responded accelerating, pipeline in our discovery of that cancer to indications been in continue novel mechanisms historically Concluding
by siRNA various those steatohepatitis with Center. the targets, Genetic a Our product or Alnylam, collaboration discovered contains including candidates NASH non-alcoholic Regeneron addressing
for are fall. ALN-HSD in NASH this data anticipated First
turn leads variant liver and have about disease. largest function will B are described, found variants clinic. B of the Alnylam second with an loss XX% Medicine, novel fatty site risk of protection lower study identified lower disease risk we has to site from of a and as Regeneron cirrhosis. New in I rare promising progressing association we function are with the developing individuals for And of examined Marion. this of of we to England lower to later about very advance of risk that, unprecedented recently NASH with disease published the PNPLAX into the additional association target siRNA XX% clinic non-alcoholic liver and loss call In target, year non-alcoholic of B. developing therapeutic developing Journal We just over ever candidate side liver the
